Histone deacetylase inhibitors in lymphoma and solid malignancies.
about
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanomaOverlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesisPhase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.Advances in epigenetic glioblastoma therapy.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathwayUridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinicHistone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cellsNovel therapeutics for aggressive non-Hodgkin's lymphoma.The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.Histone deacetylase inhibitors: emerging mechanisms of resistance.Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.The role of angiogenesis in human non-Hodgkin lymphomas.HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.Characteristics of pericardial effusions in patients with leukemia.Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphomaImmunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.Histone deacetylases and the immunological network: implications in cancer and inflammation.Epigenetic modifications as therapeutic targets.New drug therapies in peripheral T-cell lymphoma.Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.Panobinostat for the treatment of acute myelogenous leukemia.Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance.Isoform-Selective HDAC Inhibitor Therapy for Transplantation: Are We Ready for HDAC6?A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.Oncogenic H-Ras, FK228, and exogenous H2O2 cooperatively activated the ERK pathway in selective induction of human urinary bladder cancer J82 cell death.Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes
P2860
Q24658533-65FC1171-61C2-42B7-8C8A-44FBDF8C48D2Q33390343-5D13DED0-98A4-4C86-81AA-1D2CE21D20B0Q33410898-1C91CD53-F244-4603-9A3A-F13502A40885Q33567030-63391483-3206-45CB-BABD-B4420115C5F5Q34171631-CBBC71CB-BF9F-4D0F-99F5-A49AB4F0B74DQ34361211-C407258C-07D5-4282-8654-72D972D955BCQ34602263-D5636549-2C9D-4E5E-9ABA-3E9D0D62D479Q34652570-1A807375-7B3F-413C-94EE-87188BDCCA17Q34739990-EEA4E32F-5BC4-4072-94D9-0DDBB04EA626Q34952741-26549125-D120-45B4-BFCE-2F42DB32867DQ35008045-B8171F59-95EE-4B45-AE28-78F19766BE67Q35038016-6CD79670-14D8-42FD-99E6-70BC0930473FQ35096555-C2BD0386-4007-4E1D-AE3B-8E94A36AB0CFQ35111768-A6008E9F-E157-4BF4-A51A-4B0508C43618Q35223868-EA8263F0-8957-4FE8-B8D9-ED63A1305F7DQ35592607-B51AFC34-2243-4DA9-AFE7-3D6C1D3FCBE5Q36301520-AB70884C-3167-4302-A0C0-64D7E96BA7C9Q36670881-D5F61A7D-9165-4FB5-967F-77E829078CB5Q37073624-E614A087-5063-4D4E-A136-5F305C12D509Q37211962-43A6E337-DB8F-4AF3-9D7A-3C15B79789A7Q37324466-EA8F6558-6AB8-4520-9AF0-A84A03CC0F11Q37397325-F678EEAB-DF36-4D6B-BF0A-1A4F9D79D0E2Q37439209-8F36DF05-8728-4614-8571-4DAC6131D464Q37621254-59EAF771-9518-45C8-8DAC-19D354DD92CBQ37621256-4B7446A3-8B2B-484D-B3F4-45CFD0998C76Q37800011-26EB0675-EFD1-4DE7-99E1-4B3BADAC84EBQ37854715-785CA85D-88DF-4911-89D6-25D40D2B79FEQ37953956-1508F1C0-4353-490C-9CFE-92291D524D9EQ38835113-1AA99497-46B2-4B12-B4A0-DD3B362CB2C8Q38844615-A30D2F4D-1C6A-40E1-85CB-53C4D9FAD3B5Q39021652-5904C3F9-D2EE-472B-8988-9503BB57B8FFQ39868674-6C1DB69D-98F0-4A92-A666-5D308DA37B43Q41203569-457747AB-226E-4B4F-937D-6781D59CDAC0Q42402866-653CFAE8-BC46-45FE-9272-BA2F236FBC86Q42684972-20B9BFD0-F367-48A7-A133-C5F0AFC58B54Q42721017-66ED3E5E-3EE7-4BDE-8923-5C1AAB4E0F69Q53143241-F922F6BE-5C43-47D5-B225-71A42E26829FQ54610898-C39D7949-E5D2-4AFE-B0CD-0596F1763166Q58049799-5317C3FA-3CD6-4F9E-BA0B-D0D831B2D5DE
P2860
Histone deacetylase inhibitors in lymphoma and solid malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Histone deacetylase inhibitors in lymphoma and solid malignancies.
@en
Histone deacetylase inhibitors in lymphoma and solid malignancies.
@nl
type
label
Histone deacetylase inhibitors in lymphoma and solid malignancies.
@en
Histone deacetylase inhibitors in lymphoma and solid malignancies.
@nl
prefLabel
Histone deacetylase inhibitors in lymphoma and solid malignancies.
@en
Histone deacetylase inhibitors in lymphoma and solid malignancies.
@nl
P2860
P356
P1476
Histone deacetylase inhibitors in lymphoma and solid malignancies.
@en
P2093
H Miles Prince
Walid Rasheed
P2860
P304
P356
10.1586/14737140.8.3.413
P577
2008-03-01T00:00:00Z